BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 8920889)

  • 1. Human histocompatibility leukocyte antigen (HLA)-DM edits peptides presented by HLA-DR according to their ligand binding motifs.
    van Ham SM; Grüneberg U; Malcherek G; Bröker I; Melms A; Trowsdale J
    J Exp Med; 1996 Nov; 184(5):2019-24. PubMed ID: 8920889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA-DO is a negative modulator of HLA-DM-mediated MHC class II peptide loading.
    van Ham SM; Tjin EP; Lillemeier BF; Grüneberg U; van Meijgaarden KE; Pastoors L; Verwoerd D; Tulp A; Canas B; Rahman D; Ottenhoff TH; Pappin DJ; Trowsdale J; Neefjes J
    Curr Biol; 1997 Dec; 7(12):950-7. PubMed ID: 9382849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conformational alterations during biosynthesis of HLA-DR3 molecules controlled by invariant chain and HLA-DM.
    Verreck FA; Fargeas CA; Hämmerling GJ
    Eur J Immunol; 2001 Apr; 31(4):1029-36. PubMed ID: 11298327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM.
    Weber DA; Evavold BD; Jensen PE
    Science; 1996 Oct; 274(5287):618-20. PubMed ID: 8849454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editing of the HLA-DR-peptide repertoire by HLA-DM.
    Kropshofer H; Vogt AB; Moldenhauer G; Hammer J; Blum JS; Hämmerling GJ
    EMBO J; 1996 Nov; 15(22):6144-54. PubMed ID: 8947036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3.
    Ghosh P; Amaya M; Mellins E; Wiley DC
    Nature; 1995 Nov; 378(6556):457-62. PubMed ID: 7477400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HLA-DM can partially replace the invariant chain for HLA-DR transport and surface expression in transfected endocrine epithelial cells.
    Serradell L; Muntasell A; Catálfamo M; Martí M; Costa M; de Préval C; Jaraquemada D
    Tissue Antigens; 1999 May; 53(5):447-58. PubMed ID: 10372540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Negative regulation by HLA-DO of MHC class II-restricted antigen processing.
    Denzin LK; Sant'Angelo DB; Hammond C; Surman MJ; Cresswell P
    Science; 1997 Oct; 278(5335):106-9. PubMed ID: 9311912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading.
    Denzin LK; Cresswell P
    Cell; 1995 Jul; 82(1):155-65. PubMed ID: 7606781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Point mutations in or near the antigen-binding groove of HLA-DR3 implicate class II-associated invariant chain peptide affinity as a constraint on MHC class II polymorphism.
    Doebele RC; Pashine A; Liu W; Zaller DM; Belmares M; Busch R; Mellins ED
    J Immunol; 2003 May; 170(9):4683-92. PubMed ID: 12707347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Masking of a cathepsin G cleavage site in vivo contributes to the proteolytic resistance of major histocompatibility complex class II molecules.
    Burster T; Macmillan H; Hou T; Schilling J; Truong P; Boehm BO; Zou F; Lau K; Strohman M; Schaffert S; Busch R; Mellins ED
    Immunology; 2010 Jul; 130(3):436-46. PubMed ID: 20331476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant intermolecular disulfide bonding in a mutant HLA-DM molecule: implications for assembly, maturation, and function.
    Busch R; Doebele RC; von Scheven E; Fahrni J; Mellins ED
    J Immunol; 1998 Jan; 160(2):734-43. PubMed ID: 9551909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determination of the HLA-DM interaction site on HLA-DR molecules.
    Doebele RC; Busch R; Scott HM; Pashine A; Mellins ED
    Immunity; 2000 Oct; 13(4):517-27. PubMed ID: 11070170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variation in HLA-DM expression influences conversion of MHC class II alpha beta:class II-associated invariant chain peptide complexes to mature peptide-bound class II alpha beta dimers in a normal B cell line.
    Ramachandra L; Kovats S; Eastman S; Rudensky AY
    J Immunol; 1996 Mar; 156(6):2196 - 2204. PubMed ID: 8690909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The invariant chain derived fragment CLIP is an efficient in vitro inhibitor of peptide binding to MHC class II molecules.
    Hitzel C; Koch N
    Mol Immunol; 1996 Jan; 33(1):25-31. PubMed ID: 8604221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide.
    Sherman MA; Weber DA; Jensen PE
    Immunity; 1995 Aug; 3(2):197-205. PubMed ID: 7648393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-release of CLIP in peptide loading of HLA-DR molecules.
    Kropshofer H; Vogt AB; Stern LJ; Hämmerling GJ
    Science; 1995 Nov; 270(5240):1357-9. PubMed ID: 7481823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel mutants define genes required for the expression of human histocompatibility leukocyte antigen DM: evidence for loci on human chromosome 6p.
    Fling SP; Rak J; Muczynski KA; Arp B; Pious D
    J Exp Med; 1997 Nov; 186(9):1469-80. PubMed ID: 9348304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality control of MHC class II associated peptides by HLA-DM/H2-M.
    Vogt AB; Arndt SO; Hämmerling GJ; Kropshofer H
    Semin Immunol; 1999 Dec; 11(6):391-403. PubMed ID: 10625593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinetic analysis of peptide loading onto HLA-DR molecules mediated by HLA-DM.
    Vogt AB; Kropshofer H; Moldenhauer G; Hämmerling GJ
    Proc Natl Acad Sci U S A; 1996 Sep; 93(18):9724-9. PubMed ID: 8790398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.